ASH: J&J’s Tecvayli Set For Stronger Competition With CAR-Ts In Myeloma

 
• By Alaric DeArment
  
University of Salamanca, Spain, hematologist Maria-Victoria Mateos presenting the data from J&J's MajesTEC-3 trial in a press conference at the 2025 American Society of Hematology meeting. (Alaric DeArment)

More from ASH

More from Conferences